Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice

Purpose This work was undertaken to analyze the efficacy of switchback from aflibercept to ranibizumab in patients with neovascular age-related macular degeneration (nAMD) who had previously switched from ranibizumab to aflibercept. Methods This retrospective double-center study included 45 patients...

Full description

Saved in:

Bibliographic Details
Published in:	Graefe's archive for clinical and experimental ophthalmology Vol. 254; no. 4; pp. 639 - 644
Main Authors:	Despreaux, Raphaelle, Cohen, Salomon Y., Semoun, Oudy, Zambrowski, Olivia, Jung, Camille, Oubraham, Hassiba, Souied, Eric H.
Format:	Journal Article
Language:	English
Published:	Berlin/Heidelberg Springer Berlin Heidelberg 01.04.2016 Springer Nature B.V
Subjects:	Aged Aged, 80 and over Angiogenesis Inhibitors - therapeutic use Drug Substitution Female Fluorescein Angiography Follow-Up Studies Humans Intravitreal Injections Macular degeneration Male Medicine Medicine & Public Health Middle Aged Ophthalmology Ranibizumab - therapeutic use Receptors, Vascular Endothelial Growth Factor - therapeutic use Recombinant Fusion Proteins - therapeutic use Retinal Disorders Retrospective Studies Tomography, Optical Coherence Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - drug effects Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy Wet Macular Degeneration - physiopathology Choroidal neovascularization Switch Age-related macular degeneration Ranibizumab Anti-VEGF Aflibercept Switchback
ISSN:	0721-832X, 1435-702X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!